Table 3.
Drug Class a | WRA (N =2 224 263)b %b (95% CI) |
Possible WRA (N =6 094 064)b %b (95% CI) |
Non-WRA (N = 6 784 072)b %b 95% CI |
WRA vs non-WRA PRc (95% CI) |
Possible WRA vs non-WRA PRc (95% CI) |
---|---|---|---|---|---|
Controller | |||||
Long-acting β-agonist | 28.2 (24.3–32.1) | 23.7 (21.5–26.0) | 21.2 (19.1–23.3) | 1.15 (0.95–1.39) | 1.05 (0.92–1.21) |
Inhaled corticosteroid | 38.3 (33.8–42.9) | 36.0 (33.2–38.7) | 32.2 (29.6–34.8) | 1.04 (0.89–1.21) | 1.06 (0.95–1.18) |
Oral corticosteroid | 5.5 (3.8–7.3) | 3.0 (1.8–4.2) | 2.5 (1.7–3.4) | 1.29 (0.83–1.99) | 0.95 (0.62–1.45) |
Cromolyn/nedocromil | — | — | — | — | — |
Leukotriene pathway inhibitor | 16.0 (12.7–19.3) | 10.9 (9.4–12.4) | 10.5 (8.7–12.2) | 1.59 (1.22–2.07) | 1.22 (0.97–1.52) |
Methylxanthine | 1.8 (0.8–2.8) | 1.1 (0.7–1.6) | 0.3 (0.2–0.5) | 4.76 (2.06–11.0) | 2.85 (1.55–5.23) |
Anti-cholinergic | 9.9 (6.3–13.4) | 5.3 (4.3–6.3) | 3.5 (2.8–4.2) | 1.80 (1.05–3.06) | 1.18 (0.90–1.56) |
Rescue | |||||
Short-acting β-agonist | 61.2 (56.6–65.9) | 57.5 (54.5–60.4) | 50.2 (47.2–53.2) | 0.99 (0.88–1.10) | 1.02 (0.95–1.10) |
Medications used in 3 months preceding the survey interview.
Results presented as weighted annual average.
Consists of eight models where the outcome variables were drug class and the predictor variable was WRA status, adjusted for age, sex, race/ethnicity, income, health insurance, current employment status, chronic obstructive pulmonary disease (COPD), and adverse asthma outcomes.
CI, confidence interval; PR, prevalence ratio; WRA, work-related asthma; Bold text indicates significance; “–” indicates relative standard error >30%, estimate not reportable.